#1728 ADA Standards of Care for 2026

Scott and Jenny review the newly released 2026 ADA Standards of Care, praising key updates like hospital safety protocols while critiquing the "slow drift" of official guidance compared to real-world management.

Topics Discussed:

The "Slow Drift" of Guidance: Scott analyzes how standards often lag behind effective real-world management, comparing current advice to guidelines from 2018 and 2022.

GLP-1s for Type 1: The new guidance explicitly lists GLP-1 receptor agonists as a treatment option for obesity in people with Type 1 diabetes.

Technology Access: The requirement for C-Peptide levels or antibody presence has been removed for initiating insulin pumps or AID systems.

Hospital Safety: A crucial new standard mandates that basal insulin should never be held for patients with Type 1 diabetes in the hospital.

Workplace Advocacy: New language supports reasonable accommodations for adults using diabetes technology (pumps/CGMs) in the workplace.

Cannabis Warning: The standards include a new specific warning against cannabis use for those at risk of DKA due to concerns about "cannabis hyperemesis syndrome".